OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	108
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	80
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	79
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	77
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	74
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	71
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	63
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	61
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	58
A randomized, phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	58
Theranostic strategies in sarcoma: preliminary clinical evidence	55
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	54
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	44
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	44
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	43
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	43
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials	37
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	37
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	34
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	31
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential	29
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	28
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	27
Emerging treatments for chronic urticaria	26
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	26